Clinical trial
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With…
NCT00456261 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00456261 |
|---|---|
| Title | First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC |
| Official title | A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin |
| Enrollment | 110 |
| Start date | Mar 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Sep 1, 2012 |
| First posted | Apr 4, 2007 |
| Last update posted | May 3, 2022 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: